1,https://www.reuters.com/article/brief-lannett-anticipates-biosimilar-app/brief-lannett-anticipates-biosimilar-application-for-insulin-glargine-to-be-submitted-by-2022-end-idUSFWN2DO07N,2020-06-11T12:51:29Z,BRIEF-Lannett Anticipates Biosimilar Application For Insulin Glargine To Be Submitted By 2022 End,June 11 (Reuters) - Lannett Company Inc:,"* LANNETT PROVIDES UPDATE ON CLINICAL ADVANCEMENT OF BIOSIMILAR INSULIN GLARGINE, FOLLOWING FDA MEETING",* LANNETT COMPANY INC - ANTICIPATES BIOSIMILAR APPLICATION FOR INSULIN GLARGINE TO BE SUBMITTED BY END OF CALENDAR YEAR 2022,* LANNETT - FDA PROVIDED POSITIVE FEEDBACK ON CLINICAL AND CMC ADVANCEMENT OF BIOSIMILAR INSULIN GLARGINE THAT WAS CONSISTENT WITH CO’S EXPECTATIONS Source text for Eikon: Further company coverage:
2,https://www.reuters.com/article/brief-lannett-posts-q3-loss-per-share-of/brief-lannett-posts-q3-loss-per-share-of-0-43-idUSASA00O9H,2020-05-06T22:31:44Z,BRIEF-Lannett Posts Q3 Loss Per Share Of $0.43,May 6 (Reuters) - Lannett Company Inc:,* LANNETT ANNOUNCES FISCAL 2020 THIRD-QUARTER FINANCIAL RESULTS,* Q3 SALES $144.4 MILLION VERSUS REFINITIV IBES ESTIMATE OF $134.5 MILLION,* Q3 EARNINGS PER SHARE ESTIMATE $0.29 -- REFINITIV IBES DATA,"* SEES FY NET SALES $535 MILLION TO $545 MILLION, FROM $530 MILLION TO $550 MILLION","* SEES FY ASSET IMPAIRMENT CHARGES $16 MILLION, UP FROM $2 MILLION","* SEES FY CAPEX $15 MILLION TO $20 MILLION, DOWN FROM $20 MILLION TO $25 MILLION Source text for Eikon: Further company coverage:"
3,https://www.reuters.com/article/brief-lannett-to-meet-with-fda-regarding/brief-lannett-to-meet-with-fda-regarding-the-clinical-advancement-of-biosimilar-insulin-glargine-on-june-9-idUSFWN2BW0UM,2020-04-08T11:14:13Z,BRIEF-Lannett To Meet With FDA Regarding The Clinical Advancement Of Biosimilar Insulin Glargine On June 9,April 8 (Reuters) - Lannett Company Inc:,* LANNETT TO MEET WITH FDA REGARDING THE CLINICAL ADVANCEMENT OF BIOSIMILAR INSULIN GLARGINE ON JUNE 9,"* LANNETT - EXPECT DISCUSSION WITH FDA TO INCLUDE DESIGN,ENDPOINT OF ANY ADDITIONAL HUMAN STUDIES REQUIRED FOR FILING BLA",* LANNETT - EXPECT DISCUSSION WITH FDA TO INCLUDE APPROVAL OF INSULIN GLARGINE AS A BIOSIMILAR Source text for Eikon: Further company coverage:
4,https://www.reuters.com/article/brief-lannett-begins-marketing-generic-a/brief-lannett-begins-marketing-generic-adderall-xr-idUSFWN2BO0PY,2020-03-31T11:39:05Z,BRIEF-Lannett Begins Marketing Generic Adderall Xr,March 31 (Reuters) - Lannett Company Inc:,* LANNETT BEGINS MARKETING GENERIC ADDERALL® XR Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
5,https://www.reuters.com/article/brief-lannett-receives-fda-approval-for/brief-lannett-receives-fda-approval-for-dronabinol-capsules-idUSASC0A2ZW,2018-05-21T10:58:19Z,BRIEF-Lannett Receives FDA Approval For Dronabinol Capsules,May 21 (Reuters) - Lannett Company Inc:,"* LANNETT COMPANY INC - RECEIVED APPROVAL OF ABBREVIATED NEW DRUG APPLICATION FOR DRONABINOL CAPSULES USP, 2.5 MG, 5 MG AND 10 MG",* LANNETT - EXPECT TO COMMENCE MARKETING SEVERAL PRODUCTS INCLUDING DRONABINOL CAPSULES OVER COURSE OF YEAR,"* LANNETT COMPANY INC - FDA APPROVAL FOR DRONABINOL CAPSULES,THERAPEUTIC EQUIVALENT TO REFERENCE LISTED DRUG, MARINOL CAPSULES OF ABBVIE Source text for Eikon: Further company coverage:"
6,https://www.reuters.com/article/brief-lannett-reports-q3-adjusted-earnin/brief-lannett-reports-q3-adjusted-earnings-per-share-0-80-idUSASC0A07G,2018-05-07T20:35:35Z,BRIEF-Lannett Reports Q3 Adjusted Earnings Per Share $0.80,May 7 (Reuters) - Lannett Company Inc:,* LANNETT ANNOUNCES FISCAL 2018 THIRD-QUARTER FINANCIAL RESULTS,* Q3 SALES $174.4 MILLION VERSUS I/B/E/S VIEW $176.3 MILLION,* Q3 EARNINGS PER SHARE VIEW $0.79 -- THOMSON REUTERS I/B/E/S,* SEES FY 2018 GAAP NET SALES OF $685 MILLION TO $695 MILLION,* SEES FY 2018 ADJUSTED NET SALES OF $685 MILLION TO $695 MILLION,* LANNETT COMPANY SEES FY 2018 ADJUSTED GROSS MARGIN OF APPROXIMATELY 48%,"* Q3 EARNINGS PER SHARE VIEW $0.79, REVENUE VIEW $176.3 MILLION -- THOMSON REUTERS I/B/E/S",* FY2018 REVENUE VIEW $687.3 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:
7,https://www.reuters.com/article/brief-lannett-acquires-portfolio-of-gene/brief-lannett-acquires-portfolio-of-generic-products-from-endo-international-idUSASC0A00L,2018-05-07T10:54:51Z,BRIEF-Lannett Acquires Portfolio Of Generic Products From Endo International,May 7 (Reuters) - Lannett Company Inc:,* LANNETT ACQUIRES PORTFOLIO OF GENERIC PRODUCTS FROM ENDO INTERNATIONAL,"* LANNETT COMPANY INC - TRANSACTION INCLUDES 23 APPROVED AND 1 PENDING DRUG PRODUCT APPLICATIONS, PRIMARILY ORAL SOLUTIONS",* LANNETT - ACQUIRED 23 APPROVED AND ONE PENDING DRUG PRODUCT APPLICATIONS FROM UNIT OF ENDO FOR UPFRONT PAYMENT PLUS FUTURE MILESTONE PAYMENTS,"* LANNETT - EXPECT TO BEGIN LAUNCHING PRODUCTS, AFTER TRANSFER ACTIVITIES ARE COMPLETED, REGULATORY FILINGS MADE, ESTIMATED TO BE IN H2 2019 Source text for Eikon: Further company coverage:"
8,https://www.reuters.com/article/brief-lannett-appoints-patrick-lepore-ch/brief-lannett-appoints-patrick-lepore-chairman-of-board-idUSASC09Y5T,2018-04-30T11:09:46Z,BRIEF-Lannett Appoints Patrick Lepore Chairman Of Board,April 30 (Reuters) - Lannett Company Inc:,"* LEPORE WILL SUCCEED JEFFREY FARBER, WHO WILL REMAIN A MEMBER OF BOARD Source text for Eikon: Further company coverage:"
